Literature DB >> 2337747

De-differentiation with time in prostate cancer and the influence of treatment on the course of the disease.

J A Cumming1, A W Ritchie, C M Goodman, M A McIntyre, G D Chisholm.   

Abstract

There is little information on histological changes in prostate cancer during the course of the disease. We have studied 74 patients with carcinoma of the prostate who required 2 transurethral resections of the prostate (mean interval between resections 2.4 years). They constituted 18.4% of all patients with carcinoma of the prostate presenting to our clinic between January 1978 and April 1988. All tumours were staged by conventional methods and graded using the Gleason system. The Gleason sum score in those patients with tumour in both specimens increased in 49, remained constant in 12 and decreased in 7. Within this group were 34 patients who were treated expectantly. The mean Gleason sum scores in this group increased, with a concomitant increase in local tumour stage and development of metastases. Although this was not a randomised trial, there was no significant difference in survival between patients having "deferred" management and those treated immediately, either from time of diagnosis or from time of second resection. There was, however, a significant difference in the time to second resection, with the "deferred" group requiring repeat resection on average 1 year earlier. This study confirmed the concept of tumour de-differentiation with time and showed that this phenomenon occurs in both treated and untreated tumours. Although overall survival was not influenced by the type of initial therapy or its timing, local progression, as assessed by the need for further TURP, occurred earlier in those not receiving immediate therapy.

Entities:  

Mesh:

Year:  1990        PMID: 2337747     DOI: 10.1111/j.1464-410x.1990.tb14725.x

Source DB:  PubMed          Journal:  Br J Urol        ISSN: 0007-1331


  3 in total

1.  Diagnosis, prognosis and management of incidentally found prostate cancer.

Authors:  P J Davidson
Journal:  Urol Res       Date:  1993-01

2.  Change in prostate cancer grade over time in men followed expectantly for stage T1c disease.

Authors:  Todd B Sheridan; H Ballentine Carter; Wenle Wang; Patricia B Landis; Jonathan I Epstein
Journal:  J Urol       Date:  2008-01-22       Impact factor: 7.450

3.  Importance and determinants of Gleason score undergrading on biopsy sample of prostate cancer in a population-based study.

Authors:  Elisabetta Rapiti; Robin Schaffar; Christophe Iselin; Raymond Miralbell; Marie-Françoise Pelte; Damien Weber; Roberto Zanetti; Isabelle Neyroud-Caspar; Christine Bouchardy
Journal:  BMC Urol       Date:  2013-04-11       Impact factor: 2.264

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.